跳至主要内容
临床试验/NCT02216396
NCT02216396Unknown不适用

MARQUE (Managing Agitation and Quality of Life) Stream 2: A Naturalistic Two-year Cohort Study of Agitation and Quality of Life in Care Homes

University College, London1 个研究点 分布在 1 个国家目标入组 1,734 人开始时间: 2014年4月最近更新:
适应症

试验速览

阶段
不适用
入组人数
1,734
试验地点
1
主要终点
DEMQOL and DEMQOL proxy

研究概览

简要总结

One third of the population, aged over 65, live and will die with dementia. Half of people with dementia experience symptoms of agitation every month. Symptoms of agitation include restlessness, pacing, shouting and verbal or physical aggression. Many people with agitation are admitted to care homes as families find they cannot care for them at home. Within the care home, staff also often find managing people with agitation difficult and they react in a wide range of ways. Agitated behaviour takes up staff time and emotional and physical energy but they do not always know how to respond. This study is one of the streams in an integrated programme to help tackle agitation in a variety of settings from domestic environments to end of life.

Our primary hypothesis is that for people with dementia living in care homes, paid carer use of dysfunctional coping strategies predicts lower quality of life in residents with dementia and that this is more so at higher levels of agitation.

We will recruit 60-80 care homes (residential or nursing homes). We will identify all residents with dementia, and the care home manager will approach them and their family carers. After obtaining informed consent, or advice from personal or nominated consultees for those lacking capacity, we will ask people with dementia who can answer questions about their quality of life using the DEMQOL. We will also ask staff and their family carers for those who have them, to rate the quality of life of the person with dementia using the DEMQOLproxy. We will ask care home staff other questions about residents with dementia, including about agitation, using the Cohen-Mansfield Agitation Inventory (CMAI), and the care they receive. Staff will also answer questions about the ways they cope with caring stresses, using the COPE. We will measure quality of life and agitation 5 times over 16 months. We will use our results to test our theory that agitation is an important factor determining residents quality of life, and that the ways staff cope with stress affect the impact agitation has on quality of life.

详细描述

Research questions What is the relationship between paid carer coping, and agitation and quality of life in people with dementia living in care homes? What are the economic implications? What carer, resident and environmental characteristics predict better quality of life in this group, and should therefore be incorporated into our draft care home intervention before it is evaluated? Do agitation, quality of life and quality of care predict death? Primary hypothesis For people with dementia living in care homes, paid carer use of dysfunctional coping strategies predicts lower quality of life in residents with dementia and that this is more so at higher levels of agitation.

Methods Setting and sampling We will recruit care homes from across England. Our sampling frame will encompass all care homes types where people with dementia reside to ensure external validity and generalisability. We will recruit homes to ensure a representation of each provider type (voluntary, state and private) care provision (nursing, residential) and of urban/suburban and rural locations. We already carry out research with: Jewish Care, Dementia UK, Camden Adult Social Care, Springdene Care Homes group, BUPA Care Homes, Care UK and Abbey Care. We will also work with DeNDRoN ENRICH project (CC has been involved in North Thames pilot) and our project care home partners (Jewish Care, BUPA and Barchester) to recruit care homes. We have discussed with DeNDRoN ENRICH; the network has 389 research-ready care homes and is growing rapidly; our target is achievable by targeting larger homes including our collaborators; BUPA, Jewish Care and Barchester. There are around 18,000 English care homes and 80% of residents have dementia (Alzheimer's Society).

Procedures We will seek care home managers' agreement for their care home's inclusion. We will note refusal, in order to consider external validity and use its predictors in a sensitivity analysis. In included homes, we will identify through the home care staff which people cared for have dementia using a carer proxy measure, the Noticeable Problems Checklist (Levin 1989) if they do not have a known dementia diagnosis. We will do this rather than screening residents using a cognitive measure, as it will not cause distress and is independent of culture and education. We will invite all people with dementia to participate. Some will be able to give informed consent to take part, but the majority are unlikely to have capacity to do so. We will follow the Mental Capacity Act (2005) provisions when deciding whether to include people with dementia who do not have capacity, and in appointing professional consultees for those without a personal consultee as we have in previous studies(Jones et al. 2012). We will also interview the consenting primary family carer of each resident included, if they see their relative at least monthly, and all consenting care team members, who provide hands-on care. This is to understand the coping strategies used by all who care for them and the impact on residents. We will ask the paid carer working most closely with each resident with dementia to complete proxy measures. For each home we will record care home characteristics, including number of residents (in total and with dementia), staffing: resident ratios, turnover and details of regular home activities. All assessments will take place at the care home in a private room, for paid carers and residents; family carers may choose to be interviewed in the care home, in their own home or at UCL.

Measures Clinical research assistants will conduct interviews at baseline, 4, 8, 12 & 16 months.

Analysis We will test our hypothesis that paid care teams using more dysfunctional coping strategies, is associated with people with dementia having a worse subsequent quality of life (measured using paid carer DEMQOL) and that is more so when their agitation levels are higher. We will take into account the influence of agitation and other predefined carer and resident environmental characteristics (e.g. specialist dementia home; nursing staff; dementia severity; resident sex and age). Hierarchical multiple regression models will be used to allow for the repeated measurements of quality of life over time and clustering by carer team. Interaction terms will be included in the models to consider differential effects of baseline agitation levels. We will conduct a cost-consequences analysis, reporting by different coping strategies the mean per patient resource use and costs, agitation and quality adjusted life years (QALYs) as measured by the DEMQoL. The net monetary benefit, calculated as mean per patient costs and QALYs multiplied by the amount a decision maker is willing to pay for a QALY. Analysis will also be reported by coping strategy. Descriptive statistics of mean per patient costs and resource use by agitation will also be included and will follow a predefined Statistical Analysis Plan (SAP). We will obtain date and cause of death from the ONS mortality data set; the Health and Social Care Information Centre will obtain this data for us by matching NHS number and date of birth against this database.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • We will seek care home managers' agreement for their care home's inclusion. We will note refusal, in order to consider external validity and use its predictors in a sensitivity analysis. In included homes, we will identify through the home care staff which people cared for have dementia using a carer proxy measure, the Noticeable Problems Checklist (Levin 1989) if they do not have a known dementia diagnosis. We will do this rather than screening residents using a cognitive measure, as it will not cause distress and is independent of culture and education. We will invite all people with dementia to participate.
  • We will also interview the consenting primary family carer of each resident included, if they see their relative at least monthly, and all consenting care team members, who provide hands-on care.

排除标准

  • 未提供

结局指标

主要结局

DEMQOL and DEMQOL proxy

时间窗: Up to 16 months

quality of life of the person with dementia

次要结局

  • revised Modified Conflict Tactics Scale for professional carers(baseline)
  • Cohen-Mansfield Agitation Inventory(0,4,8,12,16 months)
  • Client service receipt interview(0,4,8,12,16 months)
  • Brief COPE (Coping Orientations to Problems Experienced)(baseline)
  • Maslach burnout inventory(baseline)
  • Neuropsychiatric Inventory(0,4,8,12,16 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

终止
不适用
Environmental Influence on Gambling BehaviorPathological Gambler
NCT02549781Centre Hospitalier Universitaire de Saint Etienne12
进行中(未招募)
不适用
Stereotactic Body Radiotherapy Versus Radiofrequency Ablation for Unresectable, Small (≤ 3 cm) HCCHepatocellular Carcinoma
NCT05433701Jonggi Choi178
进行中(未招募)
3 期
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive ChemotherapyMyelodysplastic Syndrome With Excess Blasts-2Acute Myeloid Leukemia
NCT04027309Stichting Hemato-Oncologie voor Volwassenen Nederland777
进行中(未招募)
不适用
Estudio en fase 3, aleatorizado, doble ciego, controlado con placebo y multicéntrico sobre la eficacia y la seguridad de cuatro ciclos de tratamiento de 12 semanas (48 semanas) con epratuzumab en pacientes con lupus eritematoso sistémico moderado a intenso (EMBODY 1). //A phase 3, randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of four 12-week treatment cycles (48 weeks total) of Epratuzumab in systemic lupus erythematosus subjects with moderate to severe disease (EMBODY 1). - EMBODY 1upus eritematoso sistémicoMedDRA version: 12.1Level: LLTClassification code 10042945Term: Systemic lupus erythematosus
EUCTR2010-018563-41-ESCB Inc.780
进行中(未招募)
3 期
Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosisFocal segmental glomerulosclerosisUrological and Genital Diseases
ISRCTN72772236Dimerix Bioscience Pty Ltd286